



Pharmaceutical Industry Residency Program

2027 - 2028

A Letter from the Dean 3

About Florida A&M University 4

Residency Program History 5

Program Overview 6

About Bristol Myers Squibb 7

BMS Post-Doctoral Program Steering Committee 8

First-Year Overview: Clinical Residency 10

Second-Year Overview: Pharmaceutical Industry 12

Current Residents 14

Alumni Remarks 15

Residency Alumni 16

Application and Recruitment Process 17

Recruitment Timeline for the 2027-2028 Cohort 18

A Letter from the Dean



Vanessa B. Sheppard, PhD
**Dean, Professor and VP Health
Science Enterprise & Research
Innovation**

Florida A&M University
College of Pharmacy and
Pharmaceutical Sciences,
Institute of Public Health

Dear Prospective Residents,

I am pleased to introduce our pharmaceutical industry residency program, established in 2009 through a collaboration between Florida A&M University and Bristol Myers Squibb (BMS). Our goal is to attract and develop a diverse group of talented pharmacists who possess clinical expertise, innovative ideas, and a commitment to improving patient outcomes. This two-year residency program covers various therapeutic areas: the first year focuses on oncology and hematology, while the second year offers a choice between neuroscience and oncology. Residents gain a unique experience that integrates clinical practice with the pharmaceutical industry.

I am excited that the Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health (FAMU CoPPS, IPH) continues to maintain a productive partnership with BMS, a global pharmaceutical company. This collaboration significantly enhances practitioners' skills and improves patient health, while also enabling residents to help train PharmD learners.

The partnership with BMS aligns perfectly with the College's vision and mission: to provide outstanding pharmaceutical education, conduct research, and engage in service activities at the state, national, and global levels within a dynamic healthcare environment.

I encourage prospective residents to consider this unique program that bridges clinical practice with the pharmaceutical industry.

Sincerely,

Vanessa B. Sheppard, PhD



About Florida A&M University

The Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health (FAMU CoPPS, IPH) program offers PharmD, PhD, MS, and BSPS degrees to its learners. With its main campus in Tallahassee, Florida, it is the first pharmacy program in the United States that has a fully accredited Institute of Public Health both on-site and throughout Florida managed by the College of Pharmacy. The College has additional pharmacy practice centers in Northeast Florida, South Florida, and Central Florida, which support the infrastructure for the College's statewide commitment to pharmacy education and public service.

The evolution of the College has witnessed the initiation of pharmacy education with just one learner beginning in 1951, to now being one of the largest colleges of pharmacy in the country. Today, the College is recognized as a leader in preparing a diverse population of learners in Florida and among HBCUs. FAMU CoPPS, IPH has a rich history of producing high-caliber graduates capable of providing exceptional pharmaceutical care. Our unique program focuses on academic excellence, research superiority, and community service; this allows us to prepare learners for leading roles in the practice of pharmacy, research, and public health.

The College reinforces its primary mission through an active role and responsibility in the delivery, outcome, and study of pharmaceutical care services it shares with other healthcare providers. The College is committed to the advancement of pharmaceutical knowledge through teaching, research, and service in a supportive and caring environment that enhances the attainment of educational excellence and the highest standards in professional and ethical practice.





Nathaniel
Eraikhuemen, PharmD

**Division Director and Professor
of Pharmacy Practice**

Florida A&M University
College of Pharmacy and
Pharmaceutical Sciences,
Institute of Public Health – South
Florida Pharmacy Practice
Center

"The Florida A&M University (FAMU) and Bristol Myers Squibb (BMS) Pharmaceutical Industry Program was founded in 2009 through collaborative efforts of both institutions as an expansion of a very successful Advanced Pharmacy Practice Education (APPE) program. Karen Cohen of BMS, and the former FAMU CoPPS, IPH Associate Dean of Clinical Services, Dr. Michael Thompson, worked closely to shape the program and ensure that students from all Historically Black Colleges and Universities (HBCUs) Pharmacy programs throughout the country have a competitive, yet unique experience to look forward to when applying from post-graduate pharmaceutical training programs.

The former Dean of the college, Dr. Henry Lewis, and Mr. Patrick Reilly, the former BMS Vice President of Medical Information, collaborated to ensure sponsorship of the program. This paved the way for Dr. Lina (Gallego) Singleton, class of 2009, who became the first resident to complete the program. By its fourth year, the program grew to admit two residents per year.

Finally, in 2015 the program evolved to include a one-year clinical training experience analogous to the American Society of Health-System Pharmacists (ASHP) Post-Graduate Year One Residency (PGY1). I, Dr. Nathaniel Eraikhuemen, as professor of Pharmacy Practice, was tasked with developing and managing the clinical portion of the training program. The second year of the program continues to focus on pharmaceutical industry training in BMS functional areas. Drs. Shanada Thomas Monestime and Marissa West were the first graduating class of the two-year program in 2017."

– Nathaniel Eraikhuemen, **Residency Program Director**



Program Overview

The FAMU-BMS Pharmaceutical Industry Residency Program provides its residents with the unique opportunity to gain clinical practice, academia, and pharma experience while completing their two-year post-doctoral training.

During the residency, residents can expect to spend the first 12 months in South Florida gaining skills and deepening their clinical acumen across a wide variety of therapeutic areas, with a focus on oncology, hematology, and neuroscience. The skills gained during the first year will help the resident acquire key knowledge of the therapeutic landscape and healthcare industry that they will apply in the second year of the program.

During the second year, residents will transition to New Jersey where they will apply their clinical knowledge to addressing unmet medical needs in Medical Affairs at Bristol Myers Squibb. Residents will spend 12 months working on Medical Communications teams to provide key deliverables.

Practice Area	Location	Length
Clinical Oncology Resident	South Florida	1 year
Medical Affairs Resident	Lawrenceville, NJ	1 year

Residency Practice Sites



FAMU College of Pharmacy
South Florida Pharmacy Practice Center
10650 State Road 84 Davie, FL 33324



Bristol Myers Squibb
3401 Princeton Pike
Lawrenceville, NJ 08648

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company firmly focused on its mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We concentrate our research efforts in the following core therapeutic areas: Solid tumors, Hematology, Cardiovascular, Immunology and Neuroscience.

At Bristol Myers Squibb, our biopharmaceutical strategy uniquely combines the reach and resources of a major pharmaceutical company with the entrepreneurial spirit and agility of a successful biotechnology company.



Innovation is at the heart of everything we do. Innovation speaks to the groundbreaking science in our laboratories, the state-of-the-art processes in our manufacturing plants, and our pioneering approach to product commercialization.

We are committed to the highest standards of ethics and integrity and promoting economic, social, and environmental sustainability. At Bristol Myers Squibb, we are passionate about science, passionate about innovation, and passionate about making a difference in the lives of patients.





Melissa Harris, BSc,
PharmD

Chief of Staff to the CEO &
Chairman of the Board
Bristol Myers Squibb


"Bristol Myers Squibb is a company committed to patients and offers tremendous opportunities for pharmacists with an interest in joining the pharmaceutical industry. I entered Bristol Myers Squibb through the Rutgers University PharmD Fellowship program, so I have first-hand experience with the impact that preceptors, mentors, and the pharmacist community have on our incoming fellows and residents. Now as executive sponsor of the program, I am proud to foster an environment where members of our PharmD program are provided opportunities to gain experience and new skills that will prepare them for future opportunities to succeed in the pharmaceutical industry."

As a leader at Bristol Myers Squibb, I know the importance of investing in and engaging talent to fulfill our company's mission for patients. The Florida A&M University Pharmaceutical Industry Residency is an important part of our talent strategy and key to cultivating the Bristol Myers Squibb culture and its future."

– Melissa Harris, **Executive Sponsor of the BMS Post-Doctoral Steering Committee**



BMS Post-Doctoral Program Steering Committee



Executive Steering Committee




Melissa Harris, BSc, PharmD
Chief of Staff to the CEO &
Chairman of the Board

Executive Sponsor



Priya Darouian, PharmD
Senior Director, Medical Customer
Experience (CX) Strategy


Head, Post-Doctoral Programs
Steering Committee Lead




Thomas Lehman, PharmD
Executive Director, WW Medical
Rheumatology

Steering Committee Co-Lead

Steering Committee Members



Catherine Merrill, PharmD
Senior Director, Clinical Research
Collaborations Lead, Oncology



Ijeoma Oyetunde, PharmD
Senior Director, WW Medical
Oncology - PRMT5 MPL



Austin Bock, PharmD
Associate Director, WW Medical
Communications



Matthew Lupo, MCIS
Executive Director, US Commercial
Regulatory Affairs



Pratik Thakkar, MRCPharm
Executive Director, Global Medical
Oncology



Peter Fendt, PharmD, MBA
Director, Commercialization Analytics,
Cell Therapy



Victoria Berger, PharmD
Director, Global Clinical Science,
Immunology



Michael Cantrell, PhD
Vice President, US Cell Therapy Medical
Affairs

First-Year Overview: Clinical Residency

In the first year, the resident will participate in clinical pharmacology and pharmacy practice with emphasis in hematology, oncology, and immunology at practice sites located in South Florida and Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health.

The resident will actively provide pharmaceutical care to patients with cancer and immunologic diseases across various practice sites. While at the College or in the hospital, they will also participate in workshops, meetings, and other engagements to promote professional growth. As a clinical resident and adjunct faculty, the resident will have the opportunity to:

- Provide pharmaceutical care and patient education within inpatient and outpatient settings
- Deliver lectures to student pharmacists, pharmacists, nurses, and medical students
- Collaborate with preceptors to educate pharmacy students
- Conduct research with the opportunity to present findings at local and potentially national or international congresses
- Interact with healthcare providers to optimize treatment regimens

Adjunct Faculty Experience

Oncology Lecture Series:

Clinical oncology residents will have the opportunity to use the clinical knowledge of oncology and hematology they acquire over the first 12 months of the program to refine their public speaking and teaching capabilities as they lead lectures to third-year pharmacy students in oncology and hematology therapeutics. This teaching experience will include writing test questions, leading labs, and developing teaching materials.

Weekly Seminar:

Residents are an integral part of the South Florida Pharmacy Practice Center faculty team. As such, residents assist with facilitating weekly seminar classes for fourth-year pharmacy students. This includes responsibilities such as leading case discussions and lectures, proctoring exams and quizzes, and conducting workshops (CV reviews/mock interviews) in support of post-doctoral application preparation.

Research Mentorship:

While learning the key principles of conducting high-quality research by leading their own research projects, oncology clinical residents are able to share the knowledge and skills they gain by serving as research mentors to a subset of fourth-year pharmacy students completing clinical research projects. This includes providing feedback on research proposals, reviewing manuscripts and posters to ensure the quality of student pharmacist clinical research.

First-Year Overview: Clinical Residency

The first-year clinical oncology resident will complete their training with Memorial Regional Hospital. This multi-site program also allows for clinical experiences at Memorial Specialty, Memorial Regional Hospital West, Memorial Sickle Cell Medical Home and Memorial Cancer Institute.

Memorial's pharmacy residents practice excellent, patient-focused pharmaceutical care, with the goals of promoting favorable patient outcomes, improving the health status of the community and achieving a high level of patient satisfaction. Residents study several clinical specialties and provide care for a wide range of patients. They also educate patients, pharmacists, nurses, physicians and other members of the healthcare team on drug-related topics.

Purpose

- Build upon Doctor of Pharmacy (PharmD) education
- Contribute to the development of clinical pharmacists responsible for medication-related care of patients with a wide range of conditions

Clinical Rotations*:

General Medicine	Oncology/Hematology
• Hospital Administration • Neurocritical Care • Ambulatory Care • Psychiatry • Advanced Hospital • Research	• Non-Malignant Hematology - Sickle Cell Disease • Inpatient Medical Oncology • Academia • Outpatient Medical Oncology • Investigational Drug Services

*Clinical rotations are subject to change

Staffing:

Residents are required to function as a clinical pharmacist in the inpatient setting **every other weekend and two of three major holidays** during the first year. Inpatient staffing responsibilities include anticoagulation and pharmacokinetic monitoring, medication reconciliation, and order verification. Residents will primarily staff in the oncology and transplant units.

Teaching and Preceptorship:

Residents will have the opportunity to precept APPE pharmacy students and develop presentation(s) for noon Lunch & Learn lectures. Residents may also have the opportunity to obtain an elective Teaching Certificate from the University of Connecticut.

Longitudinal Activities			
Formal Research Project	Medication Use Evaluation	Research Presentation*	SESHP Continuing Education Presentation
Monthly Adverse Drug Reports	Journal Club Continuing Education Presentation	Pharmacy Committee Meetings	Residency Advisory Committee Meeting

*Presented in several settings including ASHP Midyear, with possible opportunities for international conferences
SESHP: Southeast Society of Health-System Pharmacists

Second-Year Overview: Pharmaceutical Industry

In the second year, the PharmD resident will transition to central New Jersey where they will gain a diverse set of leadership skills and unique cross-functional experiences to launch a successful career in the pharmaceutical industry. The resident will be positioned on a team within the Medical Affairs organization where they can provide significant contributions to the development, launch, and lifecycle management of various assets within the BMS portfolio.

Our resident will lead critical initiatives and collaborate with a variety of US and global BMS colleagues, key opinion leaders, healthcare professionals, and other cross-functional colleagues at BMS. As a continuum from the first-year experience, the resident will be involved in providing their clinical knowledge and better meet the needs of our customers and improve patient care.

Goals

- Understand the roles and responsibilities of a PharmD in the Medical Affairs organization
- Engage with teams across the medical matrix to collaborate with key team members and complete high-priority projects
- Become an integral part of their respective teams and take ownership of key deliverables

BMS Committees:

Residents have the opportunity to gain leadership experience by taking part in BMS Fellowship and Residency Committees such as:

- Alumni Committee
- Scholarship Committee
- Recruitment Committee
- Professional Development Committee
- Community Development Committee

Mentorship:

Residents are expected to take on an active mentorship role by mentoring rotating fourth-year pharmacy students while on APPE rotations and participating in Fellow and Resident Roundtable sessions.



Second-Year Overview: Pharmaceutical Industry

This pharmaceutical industry residency provides the resident with a comprehensive 12-month experience within Medical Affairs. Through participation in cross-functional projects and strategic initiatives, the resident will gain insight into how scientific evidence is generated, interpreted, and communicated to support healthcare professionals, patients, and other key stakeholders across the healthcare landscape.

Throughout the year, the resident will collaborate with Medical Affairs colleagues and cross-functional partners to support activities that advance scientific exchange, evidence dissemination, and medical strategy. The resident will develop valuable skills in scientific communication, strategic thinking, stakeholder engagement, project management, and leadership while gaining a broad understanding of the role Medical Affairs plays throughout the product lifecycle.

The resident may have opportunities to engage with a variety of therapeutic areas that represent key areas of focus within Bristol Myers Squibb, including Oncology, Immunology, and Neuroscience. Exposure across multiple disease states and therapeutic areas will provide the resident with a broader perspective on drug development, evolving treatment landscapes, and the diverse needs of healthcare professionals and patients.

Medical Communications

Scientific Publications & Content Development

- Support the development of abstracts, congress presentations, manuscripts, scientific platforms, and other medical communication deliverables
- Collaborate with internal stakeholders, external authors, and agency partners to communicate scientific evidence in a clear, balanced, and scientifically rigorous manner
- Contribute to publication planning, scientific content development, reactive medical materials, and educational resources that support scientific exchange
- Strengthen scientific writing, content development, and project management skills while gaining experience with the review and approval processes for medical communications materials

Medical Strategy

Strategic Planning & Cross-Functional Collaboration

- Participate in initiatives that support medical strategy development and execution across the product lifecycle
- Collaborate with cross-functional partners to identify medical insights, evolving scientific trends, and opportunities to address unmet medical needs
- Gain exposure to the integration of clinical, scientific, and stakeholder perspectives that help inform medical priorities and strategic decision-making
- Develop an understanding of how Medical Affairs teams contribute to evidence generation, scientific exchange, healthcare professional engagement, and patient-centered care

Second-Year Residents



Karim Abdelhalim, PharmD
US Medical Strategy, Neuroscience

Karim is originally from Cairo, Egypt. He received his PharmD degree from Rutgers University's Ernest Mario School of Pharmacy. Throughout pharmacy school he served as Executive Board Member of the New Jersey Society of Health-System Pharmacists and Vice President of the Rho Chi Pharmacy Honor Society, and volunteered with the Promise Clinic, providing direct patient care to underserved populations alongside interdisciplinary medical teams. Through this program, Karim looks forward to making a meaningful impact on patient care and contributing to advancements in the field. As a clinical oncology pharmacy resident, Karim led a research project evaluating differences in immune-related adverse events with immunotherapies based on ethnic representation in non-small cell lung cancer. His work was presented at the IASLC World Conference on Lung Cancer, WCLC in September 2026.

Kyra, originally from Hercules, California, earned her Doctor of Pharmacy degree from Xavier University of Louisiana. During pharmacy school, she held leadership roles in national and campus organizations focused on public health and advocacy, earning the Warren P. McKenna Service Award for her dedication to service. As a clinical resident, Kyra led a research project evaluating the impact of immune checkpoint inhibitor administration timing on clinical outcomes in patients with non-small cell lung cancer. Her work was presented at the 2026 IASLC World Conference on Lung Cancer, WCLC in Seoul, South Korea. Through this program, Kyra aims to continue improving patient outcomes and advancing healthcare through research, scientific communication, and innovation.



Kyra Thompson, PharmD
WW Medical Communications, Thoracic Oncology

First-Year Resident



Denise Fiesta, PharmD
Clinical Oncology Resident

Denise, originally from Chicago, Illinois, earned her Doctor of Pharmacy degree from Chicago State University College of Pharmacy. During pharmacy school, she demonstrated a strong commitment to leadership, service, and advocacy as Class President, President of the Illinois Council of Health-System Pharmacists student chapter, student ambassador, and tutor. Denise is particularly interested in oncology and medical affairs and is passionate about advancing pharmacy practice and improving patient outcomes. During residency, she looks forward to expanding her clinical expertise, contributing to research and education, and growing as a well-rounded pharmacist and future leader.




T'yanna Harrell, PharmD
Senior Manager,
Global Medical Oncology,
Thoracic Medical Communications
Bristol Myers Squibb

"My time in the FAMU-BMS program shaped both my clinical instincts and my career path. As a first-year resident, I led research on medication adherence in EGFR-mutant non-small cell lung cancer, work that was presented at the International World Conference on Lung Cancer — an experience that taught me how clinical insight translates into real impact for patients. In my second year with Global Medical Communications in Thoracic Oncology, I found where I truly belonged — learning to shape publication plans and scientific exchange that impacts patient care, guided every step of the way by mentors who invested in my growth and challenged me to think beyond the bench. Today, I'm proud to continue that work full-time, supporting Iza Bren on the same team that helped shape me. To future residents: trust the process, lean on your mentors, and stay curious — this program didn't just prepare me for a career in medical affairs. It gave me a home in it."

- T'yanna Harrell, **WW Medical Communications, Oncology Resident 2024-2026**

"Motivated by a profound commitment to establishing a career in medical affairs, I embarked on a journey defined by deliberate decisions to meet the ever-evolving demands of the pharmaceutical industry. Faced with the pivotal decision of residency, fellowship, or an alternative path, I recognized the FAMU-BMS program as the optimal environment to cultivate the skills and character essential to my development. As a PGY-1 resident, I refined my ability to collaborate effectively within multidisciplinary teams, enhanced my research methodology and ability to synthesize complex scientific and clinical data. This momentum and solid foundation facilitated a seamless transition into my second year as a US Medical Strategy Fellow, where I engaged in purposeful projects that aligned with my professional objectives while simultaneously delivering value to the organization. The invaluable experiences and exceptional mentorship received from FAMU, BMS, Memorial Healthcare System, and the alumni network were instrumental in securing my ideal role within the medical affairs division at BMS. I am deeply grateful for the guidance and leadership that have positioned me for continued success, empowering me to make meaningful contributions to the field."


- Jenoy Merchant, **US Medical Strategy, Neuroscience Resident 2023-2025**



Jenoy Merchant, PharmD
Medical Science Liaison,
Neuroscience
Bristol Myers Squibb

"When searching for post-doctoral training programs, I sought one that would empower me as a clinician entering the pharmaceutical industry with a PharmD, equip me with a diverse professional skillset, and support me through the inevitable challenges of growth. During my residency with the FAMU/BMS program, I found all of that and more. As a PGY1 resident, I acquired essential skills in collaborating with interdisciplinary healthcare providers, leading and publishing clinical research, teaching and presenting clinical data, and expertise in immunology and oncology; all of which accelerated my integration into medical affairs. As a PGY2 resident on the US Medical Strategy team, I made meaningful contributions and took ownership of high-impact projects as a trusted team member. Furthermore, throughout my training, I benefited from a vast and ever-present network of support from leadership across BMS, FAMU, Memorial Healthcare System, and residency alumni. The experience I gained from the FAMU/BMS program enabled me to secure my ideal role within the medical affairs organization and remain at BMS. I am deeply appreciative of the impact this program has had on my professional journey and the relationships I've cultivated."

-Avery Edwards, **US Medical Strategy, Immunology Resident 2022-2024**



Avery Edwards, PharmD
Associate Director,
WW Medical Affairs,
Rheumatology
Bristol Myers Squibb

Residency Program Alumni

Ashley Hicks, PharmD

Clinical Pharmacist
US Neuroscience Medical Strategy Resident, 2024–2026

T'yanna Harrell, PharmD

Senior Manager, WW Medical Communications, Thoracic Oncology, BMS
WW Oncology Medical Communications Resident, 2024–2026

Jenoy Merchant, PharmD

Medical Science Liaison, Neuroscience, BMS
US Neuroscience Medical Strategy Resident, 2023–2025

Maxwell Okunrobo, PharmD

Medical Science Liaison, Rare Hematology, Alexion Pharmaceuticals
WW Oncology Medical Communications Resident, 2023–2025

Avery Edwards, PharmD

Associate Director, WW Medical Affairs, Rheumatology, BMS
US Immunology Medical Strategy Resident, 2022–2024

Imani Carpenter, PharmD

Associate Director, Global Oncology Publications, AstraZeneca
US & WW Oncology Medical Communications Resident, 2022–2024

Alyssa Morgan, PharmD, BCOP

Medical Science Liaison, Breast Cancer, AstraZeneca
WW Oncology Publications Resident, 2022–2023

Nabil Sukar, PharmD

Senior Medical Science Liaison, Oncology, Johnson & Johnson
US Immunology Medical Strategy Resident, 2021–2023

Franco Dickson, PharmD

Director, Global Oncology Publications, AstraZeneca
WW Oncology Publications - Early Transition Assets Resident, 2020–2022

Raena Rhone, PharmD

Senior Medical Science Liaison, Neuropsychiatry, BMS
US Immunology Medical Strategy Resident, 2020–2022

Aaron North, PharmD

Senior Medical Science Liaison, Solid Tumor Portfolio, Jazz Pharmaceuticals
US Immunoscience Medical Strategy Resident, 2019–2021

Richie Onwuchekwa Uba, PharmD

Associate Director, Clinical Research Scientist, Hematology, Genmab
WW Immuno-Oncology Publications & Scientific Content Resident, 2019–2021

Donalle Johnson, PharmD

Medical Science Liaison, Oncology, Ipsen
US Immuno-Oncology Medical Strategy Resident, 2018–2020

Imani Pelt Nosa, PharmD

Global Oncology Publications Director, Astellas Pharma
WW Early Oncology Medical Communications Resident, 2018–2020

Bryandt Douglas, PharmD

Medical Science Liaison, Immunology, Celltrion USA
WW Medical Oncology Publications Resident, 2017–2019

Victoria Spence, PharmD

Senior Medical Science Liaison, Thoracic Oncology, AstraZeneca
US Oncology Medical Strategy Resident, 2017–2019

Jessie Nia Ross, PharmD, CMPP

US Medical Lead, Next Gen Immunology Franchise, Sanofi
WW Medical Oncology Publications Resident, 2017–2018

Kevin Clarke, PharmD

Director, US Medical Affairs, Genetic Kidney Disease, Vertex Pharmaceuticals
WW Medical Oncology Publications Resident, 2016–2018

Marissa West, PharmD

Director, US Medical Oncology, Gilead Sciences
WW Medical Oncology Publications Resident, 2015–2017

Shanada Monestime, PharmD, BCOP

Director, Community Engaged Research, GO2 for Lung Cancer
WW Oncology Medical Information Resident, 2015–2017

Jade Hoang, PharmD, MBA

Director, Global Commercial Strategy, BMS
R&D Strategy and Analytics Resident, 2014–2015

Temeitope Osiyemi, PharmD

Medical Information Resident, 2014–2015

Ijeoma Oyetunde, PharmD

Senior Director, WW Medical Oncology - PRMT5 MPL, BMS
Medical Information Resident, 2013–2014

Karina Utkina, PharmD

Senior Medical Director, Hematology/Oncology, Pharmacosmos Therapeutics Inc.
R&D Strategy and Analytics Resident, 2013–2015

Dawn Bey, PharmD, MBA

Senior Director, Field HEOR, Vertex Pharmaceuticals
R&D Strategy and Analytics Resident, 2012–2013

Kiitan Babalola, PharmD, MBA

Regional Medical Scientific Director, Oncology, Merck
Medical Information Resident, 2012–2013

Christina Wright, PharmD

Senior National Director, Immunology Field Medical, Sobi Pharmaceuticals
Medical Information Resident, 2011–2012

Lina Singleton, PharmD

Senior Scientific Director, AbbVie
Medical Information Resident, 2009–2010

Eligibility Requirements:

FAMU-BMS Residents will be expected to both practice in a diverse clinical practice environment and corporate pharma company. As such, all prospective residents will require the following:

- Doctor of Pharmacy (PharmD) degree from an accredited institution prior to the start of the residency
- Selected candidates are required to obtain **pharmacist licensure in the state of Florida prior to or within 90 days** of starting the first year of residency (A Florida pharmacy intern license will be required while pharmacist licensure is pending)
- All candidates must have authorization to work in the United States. The program does not currently sponsor candidates for H-1B status to work as pharmacy residents.

Application Materials:

Required Item	Due Date
1. Letter of Intent (LOI) 2. Unofficial transcript 3. Curriculum Vitae (CV)	October 19th
(3) Letters of Recommendation	November 13th

Letters of Intent and Letters of Recommendation should be addressed to:

Nathaniel Eraikhuemen, PharmD
Division Director and Professor of Pharmacy
Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health
10650 State Road 84
Suite 200
Davie, FL 33324

Application Submission:

All application materials must be submitted electronically via the FellowMatch portal [here](#).

Interviewing will be conducted on a rolling basis once the application portal opens on **September 28th**, therefore we strongly encourage candidates to submit application materials prior to the application deadline. The deadline for all application materials is **Monday, October 19, 2026**. Recommenders will have until **Friday, November 13, 2026** to submit letters of recommendation.

Recommenders must upload their letters via the link emailed by FellowMatch/IPhO. All letter of recommendation files should be named using the following format: [Candidate Name] - Letter of Recommendation 2027-2029.

(Example: Jane Doe – Letter of Recommendation 2027-2029)

Interview Process:

Candidates should prepare to complete first round, second round, and virtual final round interviews. Select candidates will be invited to a virtual reception with Residency Program alumni and stakeholders.

Final round interviews will include an oral presentation delivered by the candidate and a clinical competency assessment.

Candidates will be selected for the available positions. All applicants will be notified of their status by the end of **December 2026**.

For additional questions, please email us at famu@bms.com or visit our [website](#) for more information.

Recruitment Timeline for the 2027-2028 Cohort



